Abstract
A suggestive case of metastatic disease from breast cancer is reported. The HER-2-positive tumor was refractory to several agents, including anti-HER-2 therapy, trastuzumab, and lapatinib. After re-induction of trastuzumab in combination with activated natural killer (NK) cell injection therapy, tumor markers decreased, and finally a synergistic effect of taxane and capecitabine led to treatment response. This case suggests that multidisciplinary therapy including an immunological approach might be a breakthrough in the treatment of refractory disease.
MeSH terms
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Breast Neoplasms / immunology
-
Breast Neoplasms / pathology
-
Breast Neoplasms / therapy*
-
Bridged-Ring Compounds / administration & dosage
-
Capecitabine
-
Carcinoma, Ductal, Breast / immunology
-
Carcinoma, Ductal, Breast / secondary
-
Carcinoma, Ductal, Breast / therapy*
-
Combined Modality Therapy
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / analogs & derivatives
-
Drug Resistance, Neoplasm
-
Female
-
Fluorouracil / administration & dosage
-
Fluorouracil / analogs & derivatives
-
Humans
-
Killer Cells, Natural / transplantation*
-
Lapatinib
-
Lung Neoplasms / immunology
-
Lung Neoplasms / secondary
-
Lung Neoplasms / therapy*
-
Middle Aged
-
Prognosis
-
Quinazolines / administration & dosage
-
Receptor, ErbB-2 / metabolism
-
Salvage Therapy
-
Taxoids / administration & dosage
-
Trastuzumab
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Bridged-Ring Compounds
-
Quinazolines
-
Taxoids
-
Lapatinib
-
Deoxycytidine
-
taxane
-
Capecitabine
-
Receptor, ErbB-2
-
Trastuzumab
-
Fluorouracil